Research programme: glucose metabolism therapeutics - XOMA

Drug Profile

Research programme: glucose metabolism therapeutics - XOMA

Alternative Names: Insulin receptor-regulating antibodies - XOMA; X 129; XMet program; XMetA; XMetD; XMetD antibody fragment (Fab); XMetS; XOMA-129

Latest Information Update: 26 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator XOMA
  • Class Antihypoglycaemics; Monoclonal antibodies
  • Mechanism of Action Insulin receptor agonists; Insulin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Type 1 diabetes mellitus; Type 2 diabetes mellitus

Highest Development Phases

  • Preclinical Diabetes mellitus; Hypoglycaemia

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Hypoglycaemia presented at the 99th Annual Meeting of the Endocrine Society (ENDO-2017)
  • 04 Apr 2016 Pharmacodynamics data from a preclinical trial in Diabetes mellitus released by XOMA
  • 09 Mar 2016 XOMA has patent protection for the lead antibody in the XMetA programme in USA (XOMA, Form 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top